LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 1 — 5, 2017 in Washington, D.C. Curis has exclusive license to CA-4948 under a collaboration agreement with Aurigene established in 2015.
Additional information follows. Abstracts can be accessed at www.aacr.org.
|Date/Time:||Monday, Apr. 3, 2017, 8:00 AM - 12:00 PM|
|Session Title:||Novel Molecular Targets 1|
|Session Category:||Experimental and Molecular Therapeutics|
|Presentation Title:||Efficacy of the IRAK4 Inhibitor CA-4948 in Patient-Derived Xenograft Models of |
Diffuse Large B Cell Lymphoma
About Curis, Inc.
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: Company Contact: James E. Dentzer Chief Financial Officer & Chief Administrative Officer 617-503-6500 email@example.com Media Contact: David Schull Russo Partners 212-845-4271 firstname.lastname@example.org